{
    "paper_id": "c6982ddcea6f30bb12a5088b3a787a856c0b7af3",
    "metadata": {
        "title": "",
        "authors": []
    },
    "abstract": [
        {
            "text": "publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Faut-il une surveillance ophtalmologique en cas de traitement de courte dur\u00e9e par hydroxychloroquine en cette p\u00e9riode d'\u00e9pid\u00e9mie au Please cite this article as: Defoort-Dhellemmes S, Faut-il une surveillance ophtalmologique en cas de traitement de courte dur\u00e9e par hydroxychloroquine en cette p\u00e9riode d'\u00e9pid\u00e9mie au",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "Sa principale toxicit\u00e9, connue de longue date, est r\u00e9tinienne. L'HCQ est cause de la maculopathie chloroquinique (ou aux APS) qui est p\u00e9rifov\u00e9olaire chez les caucasiens et parafov\u00e9olaire chez les asiatiques. En l'absence d'un arr\u00eat pr\u00e9coce du traitement la maculopathie \u00e9volue vers une atteinte globale de type pseudo-r\u00e9tinite pigmentaire.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Les principaux facteurs de risque de toxicit\u00e9 r\u00e9tinienne de l'HDC sont : -La dose quotidienne et la dur\u00e9e du traitement. Le risque de maculopathie est tr\u00e8s faible avant 5 ans de traitement si on respecte la dose recommand\u00e9e de moins de 5 mg /kg de poids r\u00e9el/jour (400 mg pour un sujet de 80 kg). L'AAO (American Academy of ophthalmolgy) ne recommande donc un premier examen de contr\u00f4le qu'\u00e0 partir de 5 ans de traitement. (Dans ces conditions la dose totale cumul\u00e9e de 1000g consid\u00e9r\u00e9e comme toxique n'est pas atteinte) (1-2). Le risque de toxicit\u00e9 r\u00e9tinienne est plus important avec les tr\u00e8s fortes doses de 800 \u00e0 2000 mg/jour, utilis\u00e9es en canc\u00e9rologie. Dans les \u00e9tudes, peu nombreuses sur le sujet, l'atteinte r\u00e9tinienne la plus pr\u00e9coce appara\u00eet au bout de 6 mois de traitement. (3-4) -Les n\u00e9phropathies. L'HCQ \u00e9tant \u00e9limin\u00e9e par le rein, le taux circulant d'HCQ est augment\u00e9 en cas d'insuffisance r\u00e9nale.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Facteurs de risque de toxicit\u00e9 r\u00e9tinienne"
        },
        {
            "text": "-Un traitement par tamoxif\u00e8ne qui augmente le risque d'environ 5 fois. -L'ob\u00e9sit\u00e9 (IMC \u2265 \u00e0 30 kg/m2). Chez les ob\u00e8ses, il est probablement pr\u00e9f\u00e9rable de prendre en compte la masse corporelle id\u00e9ale du patient (calcul\u00e9e en fonction de sa taille) plut\u00f4t que son poids r\u00e9el lors de la prescription d'HCQ. (5).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Facteurs de risque de toxicit\u00e9 r\u00e9tinienne"
        }
    ],
    "bib_entries": {
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy",
            "authors": [
                {
                    "first": "American",
                    "middle": [],
                    "last": "Academy",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Ophthalmology",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "",
            "volume": "123",
            "issn": "",
            "pages": "1386--94",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye (Lond)",
            "authors": [
                {
                    "first": "I",
                    "middle": [
                        "H"
                    ],
                    "last": "Yusuf",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Foot",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Galloway",
                    "suffix": ""
                },
                {
                    "first": "Ardern-Jones",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "R"
                    ],
                    "last": "Watson",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "L"
                    ],
                    "last": "Yelf",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Burdon",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Bishop",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "N"
                    ],
                    "last": "Lotery",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "",
            "volume": "32",
            "issn": "",
            "pages": "1168--1173",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "V"
                    ],
                    "last": "-Navajas",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Krema",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "S"
                    ],
                    "last": "Hammoudi",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "H"
                    ],
                    "last": "Lipton",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "R"
                    ],
                    "last": "Simpson",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Boyd",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Easterbrook",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Can J Ophthalmol",
            "volume": "50",
            "issn": "6",
            "pages": "442--50",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "American Academy of Ophthalmology Hydroxychloroquine Dosing Guidelines For Short, Obese Patients. Ophthalmol Retina",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "S"
                    ],
                    "last": "Leung",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "W"
                    ],
                    "last": "Neal",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "A"
                    ],
                    "last": "Wakelee",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "V"
                    ],
                    "last": "Sequist",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "F"
                    ],
                    "last": "Marmor",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Browning",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Easterbrook",
                    "suffix": ""
                },
                {
                    "first": "Lee",
                    "middle": [
                        "C"
                    ],
                    "last": "The",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Am J Ophthalmol",
            "volume": "160",
            "issn": "4",
            "pages": "809--813",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "TABREF0": {
            "text": "Faut-il une surveillance ophtalmologique en cas de traitement de courte dur\u00e9e par hydroxychloroquine en cette p\u00e9riode d'\u00e9pid\u00e9mie au COVID-19 ? 1 Traitement de courte dur\u00e9e par hydroxychloroquine L'hydroxychloroquine (HCQ, Plaquenil \u00ae) est un antipalud\u00e9en de synth\u00e8se (APS) largement utilis\u00e9 dans le traitement au long cours de maladies auto-immunes (telles que Lupus Eryth\u00e9mateux Aigu Diss\u00e9min\u00e9 ou LEAD, Polyarthrite Rhumato\u00efde, maladie de Gougerot-Sj\u00f6gren \u2026) et/ou dermatologiques. (Lucite). Ses indications ont tendance \u00e0 augmenter notamment en p\u00e9diatrie et en canc\u00e9rologie comme adjuvant de traitements oncologiques.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}